A number of recommendations to improve framework conditions for Danish life science companies are today presented to the Danish government by Lundbeck’s CEO Kåre Shultz. The overall ambition is to create a world-leading life science environment in Denmark and to double the Danish life-science export to DKK 200bn by 2025.
As chair of the government’s Growth Team for Life Science, Kåre has led the team’s work through the past seven months discussing how to ensure the best conditions for continued growth for the sector as one of the most important contributors to Danish export, employment and economic growth. Its recommendations span a number of areas including production, education, research, export and access to capital for innovative start-up companies.
Read the full report (Danish report).
The Growth Team consists of members from public institutions, academia and private companies such as Lundbeck, Novo Nordisk, Coloplast and Leo Pharma. Kåre was appointed chair of the team by the minister of growth, a testament to the importance of Lundbeck as a company and recognition of Kåre’s capabilities as a leader.